Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer
ST Martin, HM Heneghan, DC Winter - Journal of British Surgery, 2012 - academic.oup.com
Background Following neoadjuvant chemoradiotherapy (CRT) and interval proctectomy, 15–
20 per cent of patients are found to have a pathological complete response (pCR) to …
20 per cent of patients are found to have a pathological complete response (pCR) to …
[HTML][HTML] The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients
M Van den Eynde, B Mlecnik, G Bindea, T Fredriksen… - Cancer cell, 2018 - cell.com
Treatment of metastatic colorectal cancer is based upon the assumption that metastases are
homogeneous within a patient. We quantified immune cell types of 603 whole-slide …
homogeneous within a patient. We quantified immune cell types of 603 whole-slide …
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
M Maas, PJ Nelemans, V Valentini, P Das… - The lancet …, 2010 - thelancet.com
Background Locally advanced rectal cancer is usually treated with preoperative
chemoradiation. After chemoradiation and surgery, 15–27% of the patients have no residual …
chemoradiation. After chemoradiation and surgery, 15–27% of the patients have no residual …
Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy
F Mascia, G Lam, C Keith, C Garber… - Science translational …, 2013 - science.org
Cancer patients treated with anti-EGFR (epidermal growth factor receptor) drugs often
develop a dose-limiting pruritic rash of unknown etiology. The aims of our study were to …
develop a dose-limiting pruritic rash of unknown etiology. The aims of our study were to …
[HTML][HTML] Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized …
D Helbling, G Bodoky, O Gautschi, H Sun, F Bosman… - Annals of oncology, 2013 - Elsevier
Background We conducted a randomized, phase II, multicenter study to evaluate the anti-
epidermal growth factor receptor (EGFR) mAb panitumumab (P) in combination with …
epidermal growth factor receptor (EGFR) mAb panitumumab (P) in combination with …
Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment
M Ragusa, A Majorana, L Statello, M Maugeri… - Molecular cancer …, 2010 - AACR
The relationship between therapeutic response and modifications of microRNA (miRNA)
transcriptome in colorectal cancer (CRC) remains unknown. We investigated this issue by …
transcriptome in colorectal cancer (CRC) remains unknown. We investigated this issue by …
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
BACKGROUND AND PURPOSE: KRAS and BRAF are mutated in 35% and 10% of
colorectal cancers, respectively. However, data specifically for locally advanced rectal …
colorectal cancers, respectively. However, data specifically for locally advanced rectal …
[HTML][HTML] Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis
Y Hong, Y Rao - Biomedicine & Pharmacotherapy, 2019 - Elsevier
Tumor metastasis is a major cause of colorectal cancer-related deaths. The liver is a
common site of colorectal cancer metastasis. There is no effective treatment for patients with …
common site of colorectal cancer metastasis. There is no effective treatment for patients with …
Rectal cancer: neoadjuvant chemoradiotherapy
C Rödel, R Hofheinz, E Fokas - Best practice & research Clinical …, 2016 - Elsevier
The monolithic approach to apply the same schedule of preoperative 5-fluorouracil (5-FU)-or
capecitabine-based chemoradiotherapy (CRT) to all patients with clinically staged TNM …
capecitabine-based chemoradiotherapy (CRT) to all patients with clinically staged TNM …